COMBINATION CHEMOTHERAPY WITH ADRIAMYCIN (NSC-123127) AND CYCLOPHOSPHAMIDE (NSC-26271) FOR SOLID TUMORS - PHASE-2 TRIAL

Google Scholar
  • 1 January 1976
    • journal article
    • research article
    • Vol. 60  (1) , 77-83
Abstract
Adult patients [109] with metastatic carcinoma were treated at 3-4-wk intervals with a combination of adriamycin (40 mg/m2 given i.v. on Day 1) and cyclophosphamide (200 mg/m2 per day given orally in divided doses on Days 3-6). Ninety-two of 96 patients who had an adequate trial (minimum of 2 courses or progression of disease after 1 course) had followup observations of tumor sites and were considered evaluable for response. Overall objective response rates by tumor type were as follows: stage III or IV ovarian adenocarcinoma, 61% (14 of 23 patients); endometrial adenocarcinoma, 67% (4 of 6 patients); cervical adenocarcinoma, 33% (1 of 3 patients); prostatic adenocarcinoma, 18% (2 of 11 patients); testicular carcinoma, 33% (1 of 3 patients); lung carcinoma, 21% (4 of 19 patients); renal adenocarcinoma, 14% (1 of 7 patients); gastrointestinal adenocarcinoma, 18% (2 of 11 patients); melanoma, 25% (1 of 4 patients) and miscellaneous tumors, no responses in 5 patients. In patients with ovarian adenocarcinoma who had not previously received any cytotoxic chemotherapy the response rate was 80% (12 of 15 patients) with 33% (5 of 15 patients) achieving complete clinical remission. Complete remissions in these patients were maintained for periods ranging from 7 to 12+ mo. The major toxic effects were mild to moderate leukopenia, alopecia and nausea with vomiting. Hemorrhagic cystitis was observed in 3 patients. The combination of adriamycin and cyclophosphamide was an effective treatment for carcinoma of the breast (reported elsewhere), ovary and endometrium and should be considered for initial chemotherapy in patients with these tumors. Further investigations of its use for melanoma and carcinoma of the lung, prostate, kidney and gastrointestinal tract are also warranted.

This publication has 2 references indexed in Scilit: